Case Report {#sec1-1}
===========

A 41-year-old Vietnamese-born, non-immunocompromized woman presented in April 2012 with a one month history of painful nodules and discharging sinuses on her neck, upper arms, right thigh and across her lower abdomen ([Figure 1A](#fig001){ref-type="fig"}). She had been dissatisfied with the residual surgical scars which resulted from an abdominoplasty performed in Sydney, Australia in 2008. Consequently, during a trip to Vietnam, she consulted a *cosmetic specialist*, who performed liposuction and scar excision on her neck, upper arms, lower abdomen and thighs. She was taking venlafaxine for depression.

Clinical and radiological evaluation revealed subcutaneous abscesses and cavities on her right thigh, lower abdominal wall, upper arms and anterior neck. Swabs of pus from abscesses failed to isolate any bacteria on routine culture. The lesions persisted despite the empiric use of flucloxacillin and subsequently piperacillin-tazobactam over 2 weeks. Following an infectious diseases consultation rapidly-growing mycobacteria, nocardia species and fungi were considered as potential causes. HIV antibody testing was negative.

Acid-fast bacilli (AFB) were detected on microscopy of debrided tissue. Growth of mycobacterial colonies occurred within 5 days, which were subsequently identified as *Mycobacterium abscessus* subsp *abscessus* by 16s rRNA polymerase chain reaction (PCR). Susceptibility testing by Etest (ABbiodisk, Solna, Sweden) suggested *in vitro* susceptibility to amikacin and clarithromycin, intermediate susceptibility to imipenem, cefoxitin and linezolid and resistance to the fluoroquinolones, trimethoprim-sulfamethoxazole and doxycycline. Treatment was initiated in early May 2012 with intravenous amikacin 750 mg daily, intravenous cefoxitin infusion 12 g daily and oral clarithromycin 500 mg twice a day. The intention was for the parenteral agents to be given for 6 weeks with clarithromycin followed by at least 6-12 months of clarithromycin.

Within 3 weeks of commencing antimicrobial treatment, new nodules developed in her upper abdomen, right thigh and left leg ([Figure 1B](#fig001){ref-type="fig"}). Debrided tissue samples revealed no AFB on microscopy but *M.abscessus* continued to be isolated, indicating need for further source control surgery. Her treatment was complicated by a series of adverse drug reactions. The first was a generalized maculopapular rash ([Figure 1B](#fig001){ref-type="fig"}), for which cefoxitin was implicated by process of elimination. Treatment was reinstituted in late June 2012 with oral linezolid 600 mg twice a day in combination with amikacin and clarithromycin. Venlafaxine was discontinued in view of a potential interaction with linezolid (serotonin syndrome) and her usual psychiatrist was involved in her care.

The abscesses reappeared on her abdomen, thighs and left elbow in mid July 2012. However, debrided tissue no longer isolated the organism. The second adverse drug reaction occurred two weeks later when linezolid was discontinued due to pancytopenia and deranged liver function tests. Amikacin was also ceased at this time after 6-weeks uncomplicated by adverse events attributable to aminoglycoside use. With no other antibiotic options, clarithromycin was continued as monotherapy.

The recurrence of abdominal, thigh and arm abscesses in late August 2012 raised the concern for evolving resistance to clarithromycin (*erm* gene). However, further operative tissue specimens failed to demonstrate any growth of *M. Abscessus*. The possibility of a paradoxical reaction to anti-mycobacterial treatment was considered. A 2-week course of prednisone at a dose of 25 mg daily was instituted with almost complete resolution of lesions. Cessation was followed by recurrence of the paradoxical reaction and prednisone was resumed with a view to a longer course, with good effect. However, the steroid treatment was complicated by acne, alopecia, weight gain and cushingoid facial features after 2 months. Consequently, prednisone was tapered by 1mg per week until its complete discontinuation in mid-December 2012. Small nodules recurred on her lower abdomen in January 2013 and on her right thigh in May 2013 but these were small and transient. No further nodules (paradoxical reaction) or abscesses had since recurred and she completed an 18 month course of clarithromycin with full resolution of the infection. There has been no evidence of relapse in her RGM infection to date.

Discussion {#sec1-2}
==========

This case illustrates that the differential diagnosis of a surgical site infection in a returned medical tourist should include RGM such as *M. abscessus* as a potential cause and outlines the complexity of treatment. It also reports the occurrence of a paradoxical reaction occurring during antimicrobial therapy for *M. abscessus* infection which has been more often recognized as occurring with *M. tuberculosis* treatment.

Non-tuberculous mycobacteria (NTM) are present in the environment, with tap water forming an important reservoir, and have been traditionally classified as rapid, intermediate or slow growers based on Runyon's system.^[@ref1]^ Organisms categorized as RGM include *M. abscessus*, *Mycobacterium chelonae* and *Mycobacterium fortuitum*. Most rapidly-growing mycobacteria (RGM) form colonies on solid agar within 7 days from subculture, although sometimes primary cultures may take up to 2 weeks to grow.^[@ref1]^ RGM skin and soft tissue infections may complicate cosmetic surgical procedures.^[@ref2],[@ref3]^

Cosmetic surgical site infections due to RGM have been documented since 1976.^[@ref2]^ American Board of Cosmetic Surgery defines *cosmetic surgery* as any procedure which enhances patient's appearance by improving aesthetic appeal, symmetry and proportion. Varieties of procedures fall into this broad category achieved by surgery, laser therapy mesotherapy and chemical agents (hydrocolloid fillers and botulinum toxin). Seeking medical care outside one's country of residence has been referred to as medical tourism.^[@ref4]^ Due to ease of access and low costs in certain Asian and Central American countries, there has been a rise in cases of such surgeries and infections following procedures have been reported.^[@ref5]^ It is an expanding global multi-billion dollar enterprise that is projected to continue to grow significantly in the next 5 to 10 years.^[@ref4]^ In our experience we have noticed that most patients engaging in medical tourism do not receive appropriate pre-procedure counseling and that local government regulations are frequently sparse.^[@ref6]^

Investigations of RGM infection outbreaks have often failed to identify a source.^[@ref3]^ However, suboptimal infection control and inadequate local cosmetic surgical oversight systems are likely to be responsible. In particular, the use of non-sterile water to clean surgical instruments, reuse of liposuction catheters, lack of autoclaving and failure to use appropriate disinfectants have been implicated.^[@ref7]^ Due to the diverse nature of cosmetic surgery and to maintain relevance on this particular clinical case, we performed a PubMed literature search (1985-2015) with the terms *Mycobacterium abscessus, Mycobacterium bolleti*, *Mycobacterium masseliense*, *cosmetic surgical procedures*, *surgical site infections* and *medical tourism*; 38 selected cases of such infection reported in the English language are described in this review. The clinical details, treatment and outcomes of these patients are summarized in [Table 1](#table001){ref-type="table"}.^[@ref7]^

All cases involved *M. abscessus* and developed after a median incubation period of 10 weeks (IQR 4-12 weeks). The long incubation period, absence of systemic features, failure to elicit the history of cosmetic surgery abroad and initial empiric treatment as a bacterial skin and soft tissue infection often leads to delayed diagnosis. This was noted with most cases described in literature too. The reporting of *M. abscessus* infections is not mandatory in most jurisdictions. Systematic surveillance is based on voluntary reporting by clinicians.^[@ref1],[@ref7]^ A recent report of United States CDC notifying the Dominican Republic authorities of the cases of such cosmetic surgical procedures is an crucial aspect of control and public health intervention.^[@ref8]^ The number of *M. abscessus* related infections presenting worldwide as consequence of surgical procedures should raise concerns about an emerging syndrome.

The treatment of *M. abscessus* skin and soft tissue infections can be challenging. A combination of surgical debridement and antimicrobial chemotherapy is usually required. Surgery is important in decreasing disease burden, as pharmacotherapy is associated with significant limitations. Firstly, the length of treatment is not standardized, although prolonged therapy is often required for cure.^[@ref15]^ Combination therapy is usually necessary to prevent emergence of resistance.^[@ref16]^ Secondly, in vitro drug susceptibility does not reliably predict treatment response and molecular methods like detection of *erm* gene assists with therapeutic decision of long term macrolide therapy for treatment.^[@ref15],[@ref17]^ Thirdly, antibiotic therapy may be further complicated by adverse drug reactions. Hearing impairment, vestibular damage and nephrotoxicity may result from amikacin use.^[@ref1],[@ref15]^ Linezolid is associated with myelotoxicity, lactic acidosis and neuropathy.^[@ref1],[@ref15]^ The potential for serotonin syndrome when linezolid is used in combination with selective serotonin reuptake inhibitors (SSRI) and tramadol needs to be carefully considered when planning therapy. A hypersensitivity rash associated with cefoxitin treatment also occurred in our patient. Being a non-class effect, this does not preclude the future use of other agents in this class for other infections.^[@ref1],[@ref15]^ Complete resolution of lesions secondary to *M. abscessus* occurred in 36 (94.7%) of the 38 cases described in [Table 1](#table001){ref-type="table"}. Although the medical prognosis appears to be relatively good, the consequent cosmetic and psychological outcomes as a result of both disease and treatment may be significant.

Taxonomy of *Mycobacterium abscessus* has evolved to include three subspecies within its complex: *M. abscessus subsp. abscessus, M.* abscessus *subsp. bolletii*, *Mycobacterium abscessus subsp. massiliense.*^[@ref17]^ For detecting differences in these subspecies isolation and amplification of the *rpoB, secA1, sodA, recA, hsp65* and internal transcribed spacer (ITS) region between 16S and 23S RRNA region have been utilised.^[@ref18]^ Differences in the *erm* gene are associated with inducible clarithromycin resistance amongst the *M. abscessus* complex, suggesting that an accurate identification of the *erm* gene is important to predict treatment outcomes.^[@ref19]^ While *M. abscessus subsp. abscessus*, and *M. abscessus subsp. bolletii* frequently demonstrate inducible macrolide resistance, *Mycobacterium abscessus subsp. massiliense* mostly remains susceptible.^[@ref20]^

The treatment of mycobacterial infections may be associated with transient deterioration following a period of improvement, a condition termed a paradoxical reaction.^[@ref17]^ Among immune-competent patients, paradox is well-recognized in *Mycobacterium tuberculosis* complex and *Mycobacterium leprae* infections.^[@ref21],[@ref22]^ For NTM, paradoxical reaction has been reported in cases of *Mycobacterium ulcerans* skin and soft tissue infection and *M. abscessus* pulmonary disease.^[@ref23]^ This patient was deemed to have developed a paradoxical reaction on the basis of multiple negative debrided tissue cultures and the prompt and substantial response to corticosteroids. To our knowledge, this is the first reported case of the occurrence of paradoxical reaction during the treatment of a *M. abscessus* skin and soft tissue infection. The management should begin with the exclusion of treatment failure (due to intrinsic or inducible resistance and/or poor treatment compliance) and bacterial super infection. In cases of *M. ulcerans* infections, prednisone 0.5 to 1 mg/kg/day for 4 to 6 weeks has been well-tolerated and associated with marked clinical improvement within days to weeks.^[@ref24]^ Furthermore, prednisone may obviate the need for further surgical debridement.^[@ref24]^

Conclusions {#sec1-3}
===========

As medical tourism expands, the incidence of *M. abscessus* cosmetic surgical site infections is likely to rise. *M. abscessus* and other NTM should be included in the differential diagnosis of skin and soft tissue infections with features atypical for a bacterial etiology. The paradoxical reaction should be considered with recurrence of symptoms and signs during treatment despite effective therapy.

![A) Papular lesions present on the right thigh and leg on admission; B) drug induced maculopapular skin rash (yellow arrow-from Cefoxitin) and occurrence of new nodule (blue arrow).](idr-2015-4-6304-g001){#fig001}

###### 

Review of selected cases in literature. Features, treatment and outcomes of *M.abscessus* surgical site infections associated with medical tourism.

  Ref.   Age/sex    Incubation, weeks   Clinical features                           Procedure (Country)                                Surgery                               Treatment                                                                                                 Outcome
  ------ ---------- ------------------- ------------------------------------------- -------------------------------------------------- ------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  7      38/F       2                   Erythema, painful bullae, draining wounds   Abdominoplasty, back liposuction (DR)              Debridement                           Amikacin + cefoxitin, 3 wks; linezolid, 3 wks; clarithromycin, 6 months                                   Complete resolution of lesions without recurrence
  7      19/F       10                  Subcutaneous abscesses                      Abdominoplasty (DR)                                Debridement                           Clarithromycin for 2 mths                                                                                 Complete resolution of lesions without recurrence
  7      44/F       6                   Draining wounds                             Abdominoplasty, abdominal liposuction (DR)         Debridement                           Clarithromycin for 6 mths                                                                                 Complete resolution of lesions without recurrence
  7      26/F       4                   Pustules, draining wounds, erythema         Abdominoplasty, breast reduction (DR)              Debridement                           Cefoxitin and clarithromycin for 1 mnt; clarithromycin for 8 mths                                         Complete resolution of lesions without recurrence
  7      35/F       3                   Fever, draining wounds                      Abdominoplasty, breast reduction                   Debridement (DR)                      Imipenem for 3 days; amikacin and cefoxitin for 6 wks; clarithromycin for 12 mths                         Complete resolution of lesions without recurrence
  7      22/F       18                  Painful mass                                Abdominoplasty, breast elevation (DR)              Debridement                           Amikacin for 7 wks; imipenem for 1 wk and cefoxitin for 6 wks; clarithromycin for 8 mths                  Complete resolution of lesions without recurrence
  7      58/F       8                   Erythema, pain                              Abdominoplasty, abdominal liposuction (DR)         Debridement                           Levofloxacin 5 days; ciprofloxacin 2 wks, clarithromycin 4 mths                                           Complete resolution of lesions without recurrence
  7      45/F       12                  Fever, draining wounds                      Abdominoplasty, upper back liposuction (DR)        Debridement                           Azithromycin 21 months, amikacin 11 mths, cefoxitin 3 wks, imipenem 5 wks                                 Not improved at time of report
  8      19 cases   Variable            Multi-site presentation                     Breast augmentation, liposuction, abdominoplasty   14 surgery                            1 intravenous antimicrobials; 5 managed as out patients                                                   Nil deaths
  9      46/F       12                  Erythema, induration, discharging sinuses   Abdominoplasty, abdominal liposuction (DR)         Debridement                           Amikacin, cefoxitin and imipenem followed by azithromycin                                                 Recurrent mild transient erythema
  9      60/F       12                  Fever, erythema, pain                       Abdominoplasty (DR)                                Debridement                           Clarithromycin for 6 mths                                                                                 Complete resolution of lesions without recurrence
  10     48/F       12                  Pain, erythema, discharging sinuses         Breast augmentation (China)                        Debridement                           Clarithromycin and moxifloxacin for 6 mths                                                                Complete resolution of lesions without recurrence
  11     52/F       4                   Painful leg ulcers                          Abdominal liposuction (DR)                         Conservative antibiotic therapy       Clarithromycin and moxifloxacin for 8 mths                                                                Complete resolution
  12     39/F       13                  Gluteal ulcer                               Breast implants and gluteal lipofilling (Mexico)   Debridement and removal of implants   Tigecycline, amikacin, linezolid for 12 days, then moxifloxacin for 6 weeks and clarithromycin 20 weeks   Complete resolution with residual scarring
  13     5 cases    Variable            Multi-site presentation                     As above                                           Surgery + antibiotic therapy          Surgery + antibiotic therapy                                                                              Complete resolution
  14     45/F       2                   Papular lesions on legs                     Foetal stem cell transfusion                       Azithromycin,                         Imipenem and amikacin                                                                                     Improved

IP, Incubation period; DR, Dominican Republic.
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